Spots Global Cancer Trial Database for Biomarker Development for Response Prediction by DNA Mutational Analysis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Biomarker Development for Response Prediction by DNA Mutational Analysis
Official Title: Feasibility Study of Biomarker Development for Response Prediction by Large Scale DNA Mutational Analysis of Metastatic Lesions
Study ID: NCT01855061
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether it is possible to predict response to chemotherapy in patients with metastatic cancer who are treated with irinotecan by determining the mutational profile of the tumor.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, North Holland, Netherlands
Erasmsus Medical Center - Daniël den Hoed clinic, Rotterdam, South Holland, Netherlands
University Medical Center Utrecht, Utrecht, , Netherlands
Contact Details
Name: Marlies Langenberg, MD/PhD
Affiliation: UMC Utrecht
Role: PRINCIPAL_INVESTIGATOR
Name: Neeltje Steeghs, MD/PhD
Affiliation: Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam
Role: PRINCIPAL_INVESTIGATOR
Name: Ron Mathijssen, MD/PhD
Affiliation: Erasmus Medical Center - Daniël den Hoed clinic, Rotterdam
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
